Major updates to FDA-recognized Clinical and Laboratory Standards Institute breakpoints are a win for the fight against antimicrobial resistance
Journal of Clinical Microbiology · 2025
DOI: 10.1128/jcm.00106-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Microbiology, 2025. Verfasst von Romney M Humphries und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Resistance, Bacterial, Laboratories, Clinical. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antimicrobial resistance (AMR) is a pressing crisis for global health. At the front lines of detecting AMR are clinical laboratories, which perform antimicrobial susceptibility testing (AST). In recent years, the ability of laboratories to conduct this testing in the United States has been challenged by changing interpretive standards and increased regulation surrounding laboratory testing, most recently U.S. Food and Drug Administration (FDA) regulation of laboratory-developed tests. In early 2025, the FDA recognized many breakpoints published by the Clinical Laboratory Standards Institute, including for microorganisms that represented an unmet need. This unprecedented step heralds a pragmatic approach to AST by the FDA and is a major win for laboratories, clinicians, and patients in the United States and globally. In this commentary, we discuss these changes and the impact on clinical laboratories.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Romney M Humphries, Patricia J Simner
Zitieren
APA
Humphries, R. M., & Simner, P. J. (2025). Major updates to FDA-recognized Clinical and Laboratory Standards Institute breakpoints are a win for the fight against antimicrobial resistance. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00106-25
Vancouver
Humphries RM, Simner PJ. Major updates to FDA-recognized Clinical and Laboratory Standards Institute breakpoints are a win for the fight against antimicrobial resistance. Journal of Clinical Microbiology. 2025. doi:10.1128/jcm.00106-25
BibTeX
@article{Humphries2025,
author = {Humphries, Romney M and Simner, Patricia J},
title = {Major updates to FDA-recognized Clinical and Laboratory Standards Institute breakpoints are a win for the fight against antimicrobial resistance},
journal = {Journal of Clinical Microbiology},
year = {2025},
doi = {10.1128/jcm.00106-25}
}
EUVIMED